Meg Elias

6.8k total citations · 1 hit paper
15 papers, 568 citations indexed

About

Meg Elias is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Meg Elias has authored 15 papers receiving a total of 568 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Immunology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Meg Elias's work include CAR-T cell therapy research (13 papers), Biosimilars and Bioanalytical Methods (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Meg Elias is often cited by papers focused on CAR-T cell therapy research (13 papers), Biosimilars and Bioanalytical Methods (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Meg Elias collaborates with scholars based in United States, Tanzania and Netherlands. Meg Elias's co-authors include Tanya Siddiqi, William Y. Go, Frederick L. Locke, Sattva S. Neelapu, Jeff Aycock, Nancy L. Bartlett, Yizhou Jiang, John M. Rossi, Adrian Bot and Jeff Wiezorek and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Meg Elias

14 papers receiving 558 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

2017 463 citations Frederick L. Locke, Sattva S. Neelapu et al. Molecular Therapy profile →

Peers

Countries citing papers authored by Meg Elias

Since Specialization

Citations

This map shows the geographic impact of Meg Elias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meg Elias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meg Elias more than expected).

Fields of papers citing papers by Meg Elias

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meg Elias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meg Elias. The network helps show where Meg Elias may publish in the future.

Co-authorship network of co-authors of Meg Elias

This figure shows the co-authorship network connecting the top 25 collaborators of Meg Elias. A scholar is included among the top collaborators of Meg Elias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meg Elias. Meg Elias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Short-term outcome and predictors of post-operative complications following transurethral resection of the prostate among patients with benign prostate hyperplasia in Northern Tanzania: a prospective analytical study 2025 ·African Journal of Urology ·(unknown), (unknown), (unknown), Meg Elias, (unknown), (unknown), (unknown), (unknown)	0
2	Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-up of the Pivotal Zuma-1 Trial 2018 ·Biology of Blood and Marrow Transplantation ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, (unknown), Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go	1
3	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma breakdown → 2017 ·Molecular Therapy ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Armin Ghobadi, Lihua E. Budde, Adrian Bot, John M. Rossi, Yizhou Jiang, Allen Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek, William Y. Go	463
4	Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL). 2017 ·Journal of Clinical Oncology ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeffrey S. Wiezorek, William Y. Go	24
5	Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL) 2017 ·Cancer Research ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Jonathan W. Friedberg, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go	15
6	AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1 2017 ·Hematological Oncology ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick M. Reagan, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go	21
7	A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1 2016 ·Blood ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Tanya Siddiqi, Caron A. Jacobson, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Alex F. Herrera, Ann S. LaCasce, Adrian Bot, John M. Rossi, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go	23
8	ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL) 2016 ·Annals of Oncology ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Tanya Siddiqi, Ira Braunschweig, Lazaros J. Lekakis, André Goy, Januario E. Castro, Olalekan O. Oluwole, David B. Miklos, John M. Timmerman, Caron A. Jacobson, Patrick M. Reagan, Ian W. Flinn, Umar Farooq, Patrick J. Stiff, Lynn Navale, Meg Elias, Jeff Wiezorek, William Y. Go	2
9	ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL) 2016 ·Annals of Oncology ·M. Wang, Frederick L. Locke, Tanya Siddiqi, Januario E. Castro, Bijal Shah, (unknown), Lihua E. Budde, Michael Y. Choi, Claudio Anasetti, Richard E. Champlin, Stephen J. Forman, Thomas J. Kipps, Adrian Bot, John M. Rossi, Lynn Navale, Yanfei Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go	7
10	Ongoing complete remissions in phase 1 of ZUMA-1: a phase 1-2 multi-center study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in patients with refractory aggressive B cell non-Hodgkin lymphoma (NHL) 2016 ·Annals of Oncology ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Amanda F. Cashen, Lihua E. Budde, Marc S. Sherman, (unknown), Lynn Navale, Yuzhang Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go	3
11	Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL). 2016 ·Journal of Clinical Oncology ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Amanda F. Cashen, Lihua E. Budde, Adrian Bot, (unknown), Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeffrey S. Wiezorek, William Y. Go	3
12	Abstract CT135: Updated phase I results from ZUMA-1: a phase I-II multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive non-Hodgkin lymphoma (NHL) 2016 ·Cancer Research ·Armin Ghobadi, Frederick L. Locke, Sattva S. Neelapu, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Nancy L. Bartlett, Lihua E. Budde, Adrian Bot, John M. Rossi, Marika Sherman, Lynn Navale, Meg Elias, Jeff Wiezorek, William Y. Go	1
13	Ongoing Complete Remissions in ZUMA-1: A Phase 1-2 Multicenter Study of KTE-C19 (Anti-CD19 CAR T Cells) in Patients with Refractory Aggressive B Cell Non-Hodgkin Lymphoma 2016 ·Clinical Lymphoma Myeloma & Leukemia ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Amanda F. Cashen, Lihua E. Budde, Adrian Bot, (unknown), Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go	1
14	745. Updated Phase 1 Results from ZUMA-1: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 (Anti-CD19 CAR T Cells) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) 2016 ·Molecular Therapy ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Armin Ghobadi, Lihua E. Budde, Adrian Bot, John M. Rossi, Marika Sherman, Lynn Navale, Meg Elias, Jeff Wiezorek, William Y. Go	2
15	The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease. 1996 ·PubMed ·(unknown), NH Mulder, Phb Willemse, (unknown), (unknown), Jan G. Zijlstra, Meg Elias, C. Th. Smit Sibinga, Edo Vellenga, Elisabeth G.E. de Vries	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact